WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

On Behalf of the Board

 Mariusz Olejniczak CEO, WPD Pharmaceuticals  

Contact:Investor RelationsEmail: [email protected]: 604-428-7050Web: www.wpdpharmaceuticals.com 

Cautionary Statements: 

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Leave a Comment

Your email address will not be published. Required fields are marked *